SCHEMBL20689200

SCHEMBL20689200

CO[C@]1(C)CC[C@@H](n2cccc(N)c2=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.40
▸ TYK2 P29597 9/20 0.39
▸ GRM1 Q13255 1/20 0.31
▸ HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20689630 1.00 DHODH (0.40) DHODHTYK2GRM1HSD11B1
SCHEMBL21258502 1.00 DHODH (0.40) DHODHTYK2GRM1HSD11B1
SCHEMBL21948036 0.84 TYK2 (0.44) DHODHTYK2GRM1HSD11B1
SCHEMBL20689185 0.83 TYK2 (0.40) DHODHTYK2HSD11B1
SCHEMBL20697304 0.83 TYK2 (0.40) DHODHTYK2HSD11B1
SCHEMBL20688192 0.81 TYK2 (0.49) DHODHTYK2
SCHEMBL21726944 0.81 TYK2 (0.49) DHODHTYK2
SCHEMBL20689209 0.80 TYK2 (0.43) DHODHTYK2
SCHEMBL20689511 0.80 TYK2 (0.43) DHODHTYK2
SCHEMBL16794667 0.80 DHODH (0.40) DHODHTYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 — — US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 — — US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 — — US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 — — US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 — — US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 — — US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 — — US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 — — US disclosed
WO-2019023468-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2019-01-31 — — WO disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 DHODH 3066/4885TYK2 1/4885GRM1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback